Evolus/$EOLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolus
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Ticker
$EOLS
Sector
Primary listing
Employees
350
Headquarters
Website
Evolus Metrics
BasicAdvanced
$428m
-
-$0.67
1.29
-
Price and volume
Market cap
$428m
Beta
1.29
52-week high
$10.62
52-week low
$3.86
Average daily volume
910k
Financial strength
Current ratio
2.042
Quick ratio
1.5
Long term debt to equity
-564.094
Total debt to equity
-572.958
Interest coverage (TTM)
-1.63%
Profitability
EBITDA (TTM)
-23.152
Gross margin (TTM)
66.06%
Net profit margin (TTM)
-14.39%
Operating margin (TTM)
-10.42%
Effective tax rate (TTM)
-2.02%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
-9.06%
Return on equity (TTM)
245.43%
Valuation
Price to revenue (TTM)
1.397
Price to book
-14.87
Price to tangible book (TTM)
-4.42
Price to free cash flow (TTM)
-9.394
Free cash flow yield (TTM)
-10.65%
Free cash flow per share (TTM)
-0.692
Growth
Revenue change (TTM)
9.56%
Earnings per share change (TTM)
-24.65%
3-year revenue growth (CAGR)
24.49%
3-year earnings per share growth (CAGR)
-19.31%
What the Analysts think about Evolus
Analyst ratings (Buy, Hold, Sell) for Evolus stock.
Evolus Financial Performance
Revenues and expenses
Evolus Earnings Performance
Company profitability
Evolus News
AllArticlesVideos
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
Business Wire·2 days ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire·2 months ago
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolus stock?
Evolus (EOLS) has a market cap of $428M as of May 13, 2026.
What is the P/E ratio for Evolus stock?
The price to earnings (P/E) ratio for Evolus (EOLS) stock is 0 as of May 13, 2026.
Does Evolus stock pay dividends?
No, Evolus (EOLS) stock does not pay dividends to its shareholders as of May 13, 2026.
When is the next Evolus dividend payment date?
Evolus (EOLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolus?
Evolus (EOLS) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.